Search clinical trials for: PF04965842

Total 25 results

Pfizer

Completed

JAK1 Inhibitor With Medicated Topical Therapy in Adolescents With Atopic Dermatitis (JADE TEEN)

Atopic Dermatitis

Spain, United States, Taiwan, Germany, China, Hungary, Australia, Czechia, Japan, Latvia, Poland, United Kingdom, Mexico, Italy
Pfizer

Completed

AStudy to Evaluate the Bioavailability of PF 04965842 in Healthy Subjects

Healthy

Belgium
Pfizer

Completed

Study to Investigate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring Subjects

Skin Diseases | Immune System Diseases | Hypersensitivity | Hypersensitivity, Immediate | Genetic Diseases, Inborn | Skin Diseases, Genetic | Dermatitis | Eczema | Skin Diseases, Eczematous | Dermatitis, Atopic

United States, Spain, Taiwan, Germany, Canada, China, Poland, Belgium, Serbia, Brazil, Russian Federation, Israel, Latvia, Italy, Romania, Mexico, Argentina, Bulgaria, Chile, Netherlands, Slovakia
Pfizer

Completed

Study Evaluating the Mechanism of Action of PF-04965842 Monotherapy for Moderate-to-severe Atopic Dermatitis (JADE MOA)

Atopic Dermatitis

United States, Canada
Pfizer

Completed

Study Evaluating Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis (JADE Mono-2)

Dermatitis, Atopic

China, United States, Australia, Poland, Hungary, Korea, Republic of, Germany, Bulgaria, Canada, Czechia, Japan, Latvia, United Kingdom
Pfizer

Completed

Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy (JADE Compare)

Skin Diseases | Immune System Diseases | Hypersensitivity | Hypersensitivity, Immediate | Genetic Diseases, Inborn | Skin Diseases, Genetic | Dermatitis | Eczema | Skin Diseases, Eczematous | Dermatitis, Atopic

Spain, Taiwan, United States, Australia, Poland, Germany, Hungary, Bulgaria, Czechia, Japan, Korea, Republic of, Latvia, Canada, United Kingdom, Mexico, Chile, Slovakia, Italy
Pfizer

Completed

Study to Evaluate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis (JADE Mono-1)

Dermatitis, Atopic

United States, Hungary, Canada, Germany, Australia, Czechia, Poland, United Kingdom
Pfizer

Completed

A Hepatic Impairment Study for PF-04965842.

Hepatic Impairment

United States
Pfizer

Terminated

Study to Evaluate PF-04965842 in Patients With Moderate to Severe Psoriasis

Plaque Psoriasis

United States, Canada
Pfizer

Completed

Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis

Atopic Dermatitis

United States, Canada, Australia, Germany, Hungary
Pfizer

Completed

A Renal Impairment Study for PF-04965842

Renal Impairment

United States, Belgium
Pfizer

Completed

Drug Drug Interaction Study Evaluating the Effect of Fluvoxamine or Fluconazole on PK and Safety of PF-04965842.

Dermatitis, Atopic

Belgium
Pfizer

Completed

Absorption, Metabolism, Excretion and Absolute Bioavailability

Healthy

Netherlands
Pfizer

Completed

First-in-Human Study to Evaluate Safety and Tolerability of Single and Multiple Ascending Doses of Janus Kinase-1 Inhibitor PF-04965842 in Healthy Western and Japanese Subjects

Healthy

United States
Pfizer

Completed

Study of PF 04965842 Effect on MATE1/2K Activity in Healthy Participants

Healthy

Belgium
Pfizer

Completed

A Study to Assess Pharmacokinetics of PF-04965842 and Its Metabolites and Effect of Probenecid in Healthy Participants

Healthy

United States
Pfizer

Completed

A Study To Determine The Effect Of Single-dose PF-04965842 On QTc Interval In Healthy Volunteers Compared With Placebo and Moxifloxacin

Healthy Volunteers

Belgium
Pfizer

Completed

Study of PF-04965842 Effect on Dabigatran Pharmacokinetics in Healthy Participants

Healthy

Belgium
Skingenix, Inc.

Recruiting

Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns

Burns

United States
Hospices Civils de Lyon

Recruiting

Evaluation of a Management Strategy for Second-degree Fibrinous Burns Integrating a Poly-absorbent Dressing (HYDRA-B)

Burns Degree Second

France
Pfizer

Completed

Study to Assess Pharmacokinetics, Safety and Tolerability of PF-04965842 in Chinese Healthy Participants

HEALTHY

China
Pfizer

Completed

Study of PF-04965842 Effect on Rosuvastatin Pharmacokinetics in Healthy Participants

Healthy

Belgium
Pfizer

Completed

A Study to Determine the Effects of PF-04965842 on Midazolam PK in Healthy Volunteers

Phase 1

Belgium
Pfizer

Completed

Drug Interaction Study Evaluating the Effect of Rifampin on PK and Safety of PF 04965842.

Healthy

Belgium
Pfizer

Completed

A Study to Determine the Effects of PF-04965842 on the Pharmacokinetics of Oral Contraceptive Steroids in Healthy Female Subjects

Healthy Females

United States

3

Subscribe